Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Ophthotech Corp    OPHT

OPHTHOTECH CORP (OPHT)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/10/2018 01/11/2018 01/12/2018 01/16/2018 01/17/2018 Date
2.75(c) 2.79(c) 2.85(c) 2.98(c) 3.01(c) Last
670 564 465 638 229 639 501 672 341 216 Volume
-5.17% +1.45% +2.15% +4.56% +1.01% Change
More quotes
Financials ($)
Sales 2017 211 M
EBIT 2017 102 M
Net income 2017 103 M
Finance 2017 164 M
Yield 2017 -
Sales 2018 3,00 M
EBIT 2018 -95,0 M
Net income 2018 -94,0 M
Finance 2018 105 M
Yield 2018 -
P/E ratio 2017 1,08
P/E ratio 2018
EV / Sales2017 -0,27x
EV / Sales2018 0,80x
Capitalization 107 M
More Financials
Company
Ophthotech Corp. operates as a biopharmaceutical company.It focuses on discovering, developing and commercializing novel therapeutics to treat diseases of the back of the eye. It develops therapies for age-related macular degeneration.Its product candidates include Fovista Anti platelet derived... 
More about the company
Surperformance© ratings of Ophthotech Corp
Trading Rating : Investor Rating :
More Ratings
Latest news on OPHTHOTECH CORP
03:53p OPHTHOTECH : Announces Election of Jane Pritchett Henderson to Its Board of Dire..
03:51p OPHTHOTECH : Announces First Patient Enrolled in the Phase 2b Clinical Trial of ..
01/16 OPHTHOTECH : Announces First Patient Enrolled in the Phase 2b Clinical Trial of ..
01/16 OPHTHOTECH : Announces Election of Jane Pritchett Henderson, Chief Financial Off..
01/11 OPHTHOTECH CORPORATION : to Present at the 36th Annual J.P. Morgan Healthcare Co..
01/10 OPHTHOTECH CORPORATION (NASDAQ : OPHT) Files An 8-K Results of Operations and Fi..
01/10 OPHTHOTECH CORP. : Regulation FD Disclosure, Financial Statements and Exhibits (..
01/05 OPHTHOTECH CORP. : Change in Directors or Principal Officers (form 8-K)
01/02 OPHTHOTECH CORPORATION : to Present at the 36th Annual J.P. Morgan Healthcare Co..
2017 ROBBINS ARROYO LLP : Is Investigating the Officers and Directors of Ophthotech C..
More news
Sector news : Bio Therapeutic Drugs
08:48a CELGENE : Conducts Deal Talks With Juno -- WSJ
01/16 CELGENE : in Talks to Buy Juno Therapeutics -- Update
01/16 CELGENE : in Talks to Buy Juno Therapeutics
01/12 Drugmakers see a pricing blueprint in an $850,000 gene therapy
01/12 SPARK'S PRICE FOR LUXTURNA BLINDNESS : Icer
More sector news : Bio Therapeutic Drugs
Latest Tweets
01/16$OPHT: Ophthotech announces first patient enrolled in the phase 2b clinical t.. 
01/16BRIEF-Ophthotech Announces Election Of Jane Pritchett Henderson, CFO And Seni.. 
01/16Ophthotech Announces First Patient Enrolled in the Phase 2b Clinical Trial of.. 
01/16Ophthotech Announces Election of Jane Pritchett Henderson, Chief Financial Of.. 
01/16Ophthotech Announces First Patient Enrolled in the Phase 2b Clinical Trial of.. 
More tweets
Qtime:86
News from SeekingAlpha
01/12 Ophthotech (OPHT) Presents At 36th Annual J.P. Morgan Healthcare Conference -..
2017 NASDAQ BIOTECH INDEX : 54 to be added, 15 removed
2017 OHR PHARMACEUTICAL : A Compelling Acquisition Candidate And The Best Risk/Reward..
2017 Ophthotech Corporation 2017 Q3 - Results - Earnings Call Slides
2017 Ophthotech's (OPHT) CEO Glenn Sblendorio on Q3 2017 Results - Earnings Call T..
Chart OPHTHOTECH CORP
Duration : Period :
Ophthotech Corp Technical Analysis Chart | OPHT | US6837451037 | 4-Traders
Technical analysis trends OPHTHOTECH CORP
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Average target price 2,75 $
Spread / Average Target -7,7%
EPS Revisions
Managers
NameTitle
Glenn P. Sblendorio President & Chief Executive Officer
David R. Guyer Executive Chairman
Keith Westby Chief Operating Officer & Senior Vice President
David F. Carroll Chief Financial Officer & Treasurer
Axel Bolte Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
OPHTHOTECH CORP-4.49%107
GILEAD SCIENCES10.30%104 801
REGENERON PHARMACEUTICALS-2.39%39 775
VERTEX PHARMACEUTICALS5.39%39 380
GENMAB11.42%11 532
EXELIXIS, INC.-0.07%8 772